162 related articles for article (PubMed ID: 11074468)
1. Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients.
Leao JC; Kumar N; McLean KA; Porter SR; Scully CM; Swan AV; Teo CG
J Med Virol; 2000 Dec; 62(4):416-20. PubMed ID: 11074468
[TBL] [Abstract][Full Text] [Related]
2. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
Schapiro JM; Winters MA; Stewart F; Efron B; Norris J; Kozal MJ; Merigan TC
Ann Intern Med; 1996 Jun; 124(12):1039-50. PubMed ID: 8633817
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients.
De Milito A; Catucci M; Venturi G; Romano L; Incandela L; Valensin PE; Zazzi M
J Med Virol; 1999 Feb; 57(2):140-4. PubMed ID: 9892398
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
Lebbé C; Blum L; Pellet C; Blanchard G; Vérola O; Morel P; Danne O; Calvo F
AIDS; 1998 May; 12(7):F45-9. PubMed ID: 9619797
[TBL] [Abstract][Full Text] [Related]
5. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma.
Tedeschi R; Enbom M; Bidoli E; Linde A; De Paoli P; Dillner J
J Clin Microbiol; 2001 Dec; 39(12):4269-73. PubMed ID: 11724831
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.
Zolopa AR; Shafer RW; Warford A; Montoya JG; Hsu P; Katzenstein D; Merigan TC; Efron B
Ann Intern Med; 1999 Dec; 131(11):813-21. PubMed ID: 10610625
[TBL] [Abstract][Full Text] [Related]
8. Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1.
Lötsch J; Harder S; Stürmer M; Doerr HW; Geisslinger G; Staszewski S; von Hentig N
Antimicrob Agents Chemother; 2007 Sep; 51(9):3264-72. PubMed ID: 17576836
[TBL] [Abstract][Full Text] [Related]
9. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study.
Rhone SA; Hogg RS; Yip B; Sherlock C; Conway B; Schechter MT; O'Shaughnessy MV; Montaner JS
AIDS; 1998 Apr; 12(6):619-24. PubMed ID: 9583602
[TBL] [Abstract][Full Text] [Related]
10. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
[TBL] [Abstract][Full Text] [Related]
11. Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels.
Min J; Katzenstein DA
AIDS Res Hum Retroviruses; 1999 Jan; 15(1):51-5. PubMed ID: 10024052
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
[TBL] [Abstract][Full Text] [Related]
14. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients.
Fätkenheuer G; Hoetelmans RM; Hunn N; Schwenk A; Franzen C; Reiser M; Jütte A; Rockstroh J; Diehl V; Salzberger B
AIDS; 1999 Aug; 13(12):1485-9. PubMed ID: 10465071
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8.
Cassol E; Page T; Mosam A; Friedland G; Jack C; Lalloo U; Kopetka J; Patterson B; Esterhuizen T; Coovadia HM
J Infect Dis; 2005 Feb; 191(3):324-32. PubMed ID: 15633090
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia.
Bourboulia D; Aldam D; Lagos D; Allen E; Williams I; Cornforth D; Copas A; Boshoff C
AIDS; 2004 Feb; 18(3):485-93. PubMed ID: 15090801
[TBL] [Abstract][Full Text] [Related]
17. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
18. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir.
Angel JB; Kumar A; Parato K; Filion LG; Diaz-Mitoma F; Daftarian P; Pham B; Sun E; Leonard JM; Cameron DW
J Infect Dis; 1998 Apr; 177(4):898-904. PubMed ID: 9534961
[TBL] [Abstract][Full Text] [Related]
19. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
Michelet C; Ruffault A; Sébille V; Arvieux C; Jaccard P; Raffi F; Bazin C; Chapplain JM; Chauvin JP; Dohin E; Cartier F; Bellissant E
Antimicrob Agents Chemother; 2001 Dec; 45(12):3393-402. PubMed ID: 11709314
[TBL] [Abstract][Full Text] [Related]
20. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.
Harrigan PR; Hertogs K; Verbiest W; Pauwels R; Larder B; Kemp S; Bloor S; Yip B; Hogg R; Alexander C; Montaner JS
AIDS; 1999 Oct; 13(14):1863-71. PubMed ID: 10513644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
